Background. The use of a fixed-combination
antibiotic corticosteroid for
infection prophylaxis in Asian patients undergoing
phacoemulsification has not been reported. Methods. A 15-day, open-label, single-arm trial of 64 patients for
phacoemulsification with
intraocular lens (IOL) implantation is described. Patients applied
moxifloxacin 0.5%/
dexamethasone 0.1% (Vigadexa)
eye drops four times daily before and until 15 days after surgery. Anterior chamber (AC) reaction, visual acuity, ocular
pain and signs, and intraocular pressure (IOP) were assessed at baseline and on postoperative days 1, 3, 8, and 15. Results. At day 15, 55 (91.7%) patients scored 0 (<5 cells) in AC reaction. No surgery-related
infection occurred. Mean best-corrected visual acuity improved 0.5 logMAR from baseline to 0.0 logMAR (P < .0001). Mean IOP remained at 12-13 mm Hg over the 15-day treatment. Only 2 patients (3.1%) reported minimum ocular
pain. Two (3.1%) patients were shifted to
prednisolone acetate for severe
inflammation. At the end of the study period, 8.3% were given
fluorometholone for 1 week for AC reaction grade >0. No
drug-related adverse event was reported. Conclusion. Following
phacoemulsification and IOL implantation, the topical combination
moxifloxacin 0.5%/
dexamethasone 0.1% was effective in preventing
infection and controlling
inflammation and was well tolerated.